TW200635899A - Chemical compounds - Google Patents
Chemical compoundsInfo
- Publication number
- TW200635899A TW200635899A TW094145875A TW94145875A TW200635899A TW 200635899 A TW200635899 A TW 200635899A TW 094145875 A TW094145875 A TW 094145875A TW 94145875 A TW94145875 A TW 94145875A TW 200635899 A TW200635899 A TW 200635899A
- Authority
- TW
- Taiwan
- Prior art keywords
- chemical compounds
- manufacture
- relates
- cancer
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula (I): which possess CSF-1R kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63917704P | 2004-12-22 | 2004-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200635899A true TW200635899A (en) | 2006-10-16 |
Family
ID=36602125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW094145875A TW200635899A (en) | 2004-12-22 | 2005-12-22 | Chemical compounds |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR053992A1 (en) |
TW (1) | TW200635899A (en) |
WO (1) | WO2006067445A2 (en) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101367748B (en) | 2004-01-28 | 2014-03-12 | 三井化学株式会社 | Amide derivatives, process for production of same, and method for application thereof as insecticide |
MY162590A (en) | 2005-12-13 | 2017-06-30 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors |
US20080312206A1 (en) * | 2005-12-22 | 2008-12-18 | Astrazeneca Ab | Chemical Compounds-149 |
FR2903107B1 (en) * | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | IMIDAZOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
FR2903105A1 (en) | 2006-07-03 | 2008-01-04 | Sanofi Aventis Sa | 2-BENZOYL-IMIDAZOPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
WO2008057775A2 (en) * | 2006-10-27 | 2008-05-15 | Bristol-Myers Squibb Company | Heterocyclic amide compounds useful as kinase inhibitors |
CL2008000191A1 (en) | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | COMPOUNDS DERIVED FROM 4-AMINO-CINNOTINA-3-CARBOXAMIDA; CSF-1R QUINASA INHIBITORS; YOUR PREPARATION PROCESS; AND ITS USE TO TREAT CANCER. |
EP3495369B1 (en) | 2007-06-13 | 2021-10-27 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
CN101808518A (en) | 2007-06-27 | 2010-08-18 | 默沙东公司 | Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors |
EP2170076B1 (en) | 2007-06-27 | 2016-05-18 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
WO2009111280A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
EP2253617A1 (en) | 2009-05-20 | 2010-11-24 | Bayer CropScience AG | Halogenated compounds as pesticides |
EA025520B1 (en) | 2009-05-22 | 2017-01-30 | Инсайт Холдингс Корпорейшн | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS |
MX2011012262A (en) | 2009-05-22 | 2012-01-25 | Incyte Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors. |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
SI3354652T1 (en) | 2010-03-10 | 2020-08-31 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
SG10201910912TA (en) | 2010-05-21 | 2020-01-30 | Incyte Corp | Topical Formulation for a JAK Inhibitor |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
BR112013012502A2 (en) | 2010-11-19 | 2019-03-06 | Incyte Corporation | substituted cyclobutyl pyrrolopyridine and derivative pyrrolopyrimidine derivatives as jak inhibitors |
HUE031585T2 (en) | 2011-03-16 | 2017-07-28 | Mitsubishi Tanabe Pharma Corp | Sulfonamide compounds having trpm8 antagonistic activity |
MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
TW201313721A (en) | 2011-08-18 | 2013-04-01 | Incyte Corp | Cyclohexyl azetidine derivatives as JAK inhibitors |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
UA111854C2 (en) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS |
TWI519515B (en) | 2011-12-21 | 2016-02-01 | 諾維拉治療公司 | Hepatitis b antiviral agents |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
EA027280B1 (en) | 2012-08-28 | 2017-07-31 | Янссен Сайенсиз Айрлэнд Юси | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
SG11201503695XA (en) | 2012-11-15 | 2015-06-29 | Incyte Corp | Sustained-release dosage forms of ruxolitinib |
CA2899706C (en) | 2013-02-28 | 2021-10-19 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
EA030705B1 (en) | 2013-03-06 | 2018-09-28 | Инсайт Холдингс Корпорейшн | Processes and intermediates for making a jak inhibitor |
US9895349B2 (en) | 2013-04-03 | 2018-02-20 | Janssen Sciences Ireland Us | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
MX360455B (en) | 2013-05-14 | 2018-11-01 | Active Biotech Ab | N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors. |
JO3603B1 (en) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
NO3024819T3 (en) | 2013-07-25 | 2018-07-21 | ||
ES2792549T3 (en) | 2013-08-07 | 2020-11-11 | Incyte Corp | Sustained-release dosage forms for a JAK1 inhibitor |
CA2923712C (en) | 2013-10-23 | 2021-11-02 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
EP3074378A4 (en) * | 2013-11-25 | 2017-05-10 | Novogen Ltd. | Functionalised and substituted indoles as anti-cancer agents |
EP3079682A4 (en) * | 2013-12-13 | 2017-08-30 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
WO2015089479A1 (en) | 2013-12-13 | 2015-06-18 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
RU2702109C1 (en) | 2014-02-05 | 2019-10-04 | Новира Терапьютикс, Инк. | Combined therapy for treating hepatitis b infections |
CN110483484A (en) | 2014-02-06 | 2019-11-22 | 爱尔兰詹森科学公司 | Sulfamoyl pyrrole amides derivative and its purposes for being used to treat hepatitis B as drug |
CN106456773A (en) | 2014-02-28 | 2017-02-22 | 因赛特公司 | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
CA2965178C (en) | 2014-10-22 | 2023-09-26 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
CN107847762A (en) | 2015-03-19 | 2018-03-27 | 诺维拉治疗公司 | Azacyclooctane and azacyclo- nonane derivatives and the method for treating hepatitis B infection |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
WO2017007755A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
LT3319959T (en) | 2015-07-06 | 2021-12-27 | Alkermes, Inc. | Hetero-halo inhibitors of histone deacetylase |
EP3356328A1 (en) | 2015-09-29 | 2018-08-08 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
US11014882B2 (en) | 2016-03-09 | 2021-05-25 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
PT3426243T (en) | 2016-03-09 | 2021-08-19 | Raze Therapeutics Inc | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
EP3442524A2 (en) | 2016-04-15 | 2019-02-20 | Novira Therapeutics Inc. | Combinations and methods comprising a capsid assembly inhibitor |
CN113912586B (en) | 2016-08-31 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | Oxopyridine amide derivatives, preparation method thereof and application thereof in medicines |
SG11201906164RA (en) | 2017-01-11 | 2019-08-27 | Rodin Therapeutics Inc | Bicyclic inhibitors of histone deacetylase |
CN110573500B (en) | 2017-05-24 | 2020-12-08 | 上海和誉生物医药科技有限公司 | N- (nitrogen heterocyclic aryl) lactam-1-formamide derivative and preparation method and application thereof |
JOP20200001A1 (en) | 2017-07-11 | 2022-10-30 | Vertex Pharma | Carboxamides as modulators of sodium channels |
JP7152471B2 (en) | 2017-08-07 | 2022-10-12 | ロダン・セラピューティクス,インコーポレーテッド | Bicyclic inhibitor of histone deacetylase |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
PL3746429T3 (en) | 2018-01-30 | 2022-06-20 | Incyte Corporation | Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
WO2019191684A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Treatment of hidradenitis suppurativa using jak inhibitors |
US20210267203A1 (en) | 2018-06-29 | 2021-09-02 | Syngenta Participations Ag | Pesticidally active azole-amide compounds |
US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
JP2022523434A (en) | 2019-03-08 | 2022-04-22 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | Pesticide-active azole-amide compound |
WO2020188027A1 (en) | 2019-03-20 | 2020-09-24 | Syngenta Crop Protection Ag | Pesticidally active azole amide compounds |
JP2022525809A (en) | 2019-03-22 | 2022-05-19 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | N- [1- (5-bromo-2-pyrimidine-2-yl-1,2,4-triazole-3-yl) ethyl] -2-cyclopropyl-6- (trifluoromethyl) pyridine as an insecticide -4-Carboxamide Derivatives and Related Compounds |
TW202102489A (en) | 2019-03-29 | 2021-01-16 | 瑞士商先正達農作物保護公司 | Pesticidally active diazine-amide compounds |
CN113661165A (en) | 2019-04-05 | 2021-11-16 | 先正达农作物保护股份公司 | Pesticidally active diazine-amide compounds |
US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
MA56783B1 (en) | 2019-08-08 | 2023-10-31 | Servier Lab | PROCESS FOR PREPARING IVOSIDENIB AND AN INTERMEDIATE THEREOF |
WO2021037614A1 (en) | 2019-08-23 | 2021-03-04 | Syngenta Crop Protection Ag | Pesticidally active pyrazine-amide compounds |
WO2021122645A1 (en) | 2019-12-20 | 2021-06-24 | Syngenta Crop Protection Ag | Pesticidally active azole-amide compounds |
BR112022017093A2 (en) | 2020-02-27 | 2023-02-14 | Syngenta Crop Protection Ag | DIAZINE-BISAMIDE COMPOUNDS ACTIVE IN PESTICIDE TERMS |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
TW202300142A (en) * | 2021-05-24 | 2023-01-01 | 大陸商上海和譽生物醫藥科技有限公司 | Acid salt of crystalline csf-1r inhibitor, and preparation method therefor and use thereof |
WO2022258481A1 (en) | 2021-06-09 | 2022-12-15 | Syngenta Crop Protection Ag | Pesticidally active diazine-amide compounds |
CN115724791A (en) * | 2022-10-10 | 2023-03-03 | 安徽金禾化学材料研究所有限公司 | Preparation method of 2-methyl-3-nitro-5-aminopyridine |
CN115611806A (en) * | 2022-11-08 | 2023-01-17 | 江苏中旗科技股份有限公司 | Preparation method of 4-trifluoromethyl-3-cyanopyridine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9623833D0 (en) * | 1996-11-16 | 1997-01-08 | Zeneca Ltd | Chemical compound |
WO2000055120A1 (en) * | 1999-03-17 | 2000-09-21 | Astrazeneca Ab | Amide derivatives |
GB0414631D0 (en) * | 2004-06-30 | 2004-08-04 | Reckitt Benckiser Nv | Packaging for moisture sensitive material |
-
2005
- 2005-12-22 WO PCT/GB2005/004985 patent/WO2006067445A2/en not_active Application Discontinuation
- 2005-12-22 TW TW094145875A patent/TW200635899A/en unknown
- 2005-12-22 AR ARP050105491A patent/AR053992A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR053992A1 (en) | 2007-05-30 |
WO2006067445A2 (en) | 2006-06-29 |
WO2006067445A3 (en) | 2006-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200635899A (en) | Chemical compounds | |
TW200634003A (en) | Chemical compounds | |
TW200616974A (en) | Chemical compounds | |
MX2007008924A (en) | Chemical compounds. | |
TW200621259A (en) | Chemical compounds | |
TW200736234A (en) | Chemical compounds | |
TW200621730A (en) | Chemical compounds | |
WO2007071963A3 (en) | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents | |
WO2007113558A8 (en) | Quinazolinone derivatives having b-raf inhibitory activity | |
MX2009004908A (en) | Chemical compounds. | |
MX2008013212A (en) | 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors. | |
MX2009004906A (en) | Heterocyclyc sulfonamides having edg-i antagonistic activity. | |
MX2010007523A (en) | Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents. | |
WO2008068507A3 (en) | 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment | |
MY143565A (en) | Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof | |
NO20070199L (en) | Substituted quinazolones as anti-cancer agents | |
MY139302A (en) | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | |
TW200621762A (en) | Novel compounds | |
MY186126A (en) | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | |
TN2012000062A1 (en) | Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer | |
SG148177A1 (en) | Novel cis-imidazolines | |
TW200635878A (en) | Hydroxybiphenylcarboxylic acids and derivatives, processes for preparing them and their use | |
IL180136A0 (en) | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer | |
TW200604182A (en) | Substituted n-cyclohexylimidazolinones, process for their preparation and their use as medicaments | |
TW200604196A (en) | New quinuclidine derivatives and pharmaceutical compositions comprising them |